Subsequent stratification by in-hospital SGLT2 inhibitor use (users vs. non-users) across diagnostic groups revealed 124 users and 97 non-users in the primary cohort, with subgroup distributions (T2DM vs. CAD + T2DM: 27 users/28 non-users; HTN + T2DM vs. CAD + HTN + T2DM: 97 users/69 non-users) showing persistent risk factor differences (P < 0.05; Supplementary Tables S5, S6). This evidence concerns the gene SLC5A2 and coronary artery disorder.